
Keywords: AI; aromatase inhibitor; AR; androgen receptor; CAF; cancer-associated fibroblast; CBR; clinical benefit rate; CDK; cyclin-dependent kinase; ctDNA; circulating tumor DNA; DNMT3B; DNA methyltransferase 3B; ER; estrogen receptor; ESR1; ER gene; HDAC1; histo